Novel Food Ingredient Approval in Thailand: The 15-Year Rule

An ingredient that has been sold in North American or European supplement markets for decades can still be brand new as far as Thai FDA is concerned. Thailand's novel food framework does not measure an ingredient's global track record; it measures documented use inside Thailand specifically, and an ingredient without that documentation triggers a safety assessment that has to clear before the product it belongs to can be approved at all.

What actually makes an ingredient novel here

MOPH Notification No. 376 B.E. 2559 (2016) governs novel food in Thailand and defines a novel food as any food substance used continuously as human food for less than 15 years prior to the date of application. The threshold is assessed against Thai use records, not against how established the ingredient is anywhere else. An ingredient with decades of history in Western supplement markets can still have little or no documented Thai food-use record, which is enough to push it into the novel food pathway regardless of its reputation elsewhere. Exotic fruit extracts such as acai and maqui berry, algal-derived DHA from non-traditional sources, bioavailability-enhanced nutrient forms with limited Thai food history, and functional peptides are examples that commonly get treated as novel under this rule.

The trigger here is documentation, not assumption. A brand may sincerely believe an ingredient is well established in Thailand and still find that the specific kind of food-use records Thai FDA requires simply do not exist for it. Determining novelty is the applicant's responsibility, and it has to happen before the product approval application is submitted, not somewhere along the way.

This is a different question from whether an ingredient is safe, and brands sometimes conflate the two. An ingredient can have an excellent global safety record, decades of use in the United States or the European Union, and still trigger Thailand's novel food pathway purely because nobody has ever compiled and submitted the Thai-specific use documentation Thai FDA is asking for. The novel food question is administrative and evidentiary before it is scientific: it asks what can be proven about Thai use history, not what is true about the ingredient's safety profile in general.

What the safety assessment actually involves

Before a novel ingredient can go into a product sold in Thailand, a safety assessment has to be completed by a Thai FDA-recognized risk assessment center. Thai FDA does not conduct this assessment directly. A designated institution, typically a food science faculty at a major Thai research university, does the work, and Thai FDA then reviews and either accepts or conditions the outcome.

The manufacturer or importer engages the assessment center directly, and the evidence package it requires includes documented historical use data, whatever toxicological and safety studies are available, the proposed maximum level of use, the intended consumer population, and any adverse effect data on record. The center produces a formal safety assessment report and submits it to Thai FDA; if Thai FDA accepts it, the acceptance comes with specific permitted conditions of use, including a maximum level, the applicable product types, and any labeling conditions attached to the ingredient going forward.

None of this moves quickly. From the point an assessment center is engaged to Thai FDA's acceptance of the report typically runs 6 to 18 months, depending on the ingredient's complexity and how much existing safety data is available to draw on. A formula built around an untested novel ingredient is committing to the long end of that range by default.

The evidence package matters as much as the timeline. A submission built on thin historical use data, or on toxicological studies that do not directly address the proposed level of use or intended population, invites additional questions from the assessment center and from Thai FDA in turn, and each round of questions adds months to an already long process. Brands that come to the assessment center with a genuinely thorough evidence package, rather than the minimum required to open the file, tend to land on the shorter end of the 6-to-18-month range rather than the longer end.

Building this into a formula from day one

A formula screening should be the very first step in any Thailand supplement project, well before a launch date gets set anywhere. Every ingredient in the formula needs checking against both the Thai positive list and the 15-year use threshold, because a single novel ingredient in an otherwise straightforward formula can add more than a year to the market entry timeline, and that delay is not recoverable once the project is already underway with a launch date attached to it.

The novel food pathway and the standard product approval pathway run on separate tracks, and they do not converge. A brand cannot file for product approval and hope the novel ingredient question resolves itself in parallel. Thai FDA will not approve a product containing an unapproved novel ingredient under any circumstances, which means the safety assessment has to be complete, with Thai FDA's result already in hand, before the product application is even submitted.

This sequencing requirement is easy to underestimate when a brand is used to markets where a novel ingredient question and a product registration can move on parallel tracks, with the ingredient question resolved conditionally while the broader file proceeds. Thailand does not offer that flexibility. Treating the novel food screening as the actual first milestone of a Thailand project, ahead of formula finalization, ahead of label design, ahead of any commercial commitment to a launch window, is what keeps a genuinely novel ingredient from quietly becoming the reason an entire market entry plan slips by more than a year.

Screening a formula against the Thai positive list and the 15-year threshold before committing to a market entry timeline is what keeps a novel ingredient from becoming a surprise nine months into a project that assumed it wasn't one. Where an ingredient does turn out to be novel, the real decision is whether the realistic 6-to-18-month assessment timeline is acceptable or whether a formula adjustment that removes the ingredient gets the product to market faster, and that decision needs accurate numbers behind it before it gets made. DeeMED Consulting screens client formulas against Thailand's novel food rules as the first step of any supplement market entry project, working alongside the broader ingredient approval and novel food process that governs the rest of the formulation.